Set to the tune of the Beatles’ song, “Let It Be”, we present words of wisdom from the Third Quarter (Q3). These words of wisdom were not whispered, as in the “Let It Be” song lyrics, but spoken confidently with precise experimental facts by Assoc Prof, Dr. Richard Gordon, from the Queensland University of Technology’s Translational Research Institute (QUT-TRI) during podium presentations on RRx-001 (nibrozetone) at the International Parkinson and Movement Disorder Society (MDS) and the Society for Neuroscience (SfN) conferences.
Another highlight from Q3 also centered on neuroprotection was the award of a grant from the Department of Defense (DoD) for the evaluation of RRx-001 as a medical countermeasure against neurologic toxic exposures.
On what date will important manuscripts that describe in detail these unprecedented neuroprotective effects with RRx-001 be submitted to journals?
There will be an answer — in Q4.
Until next time!
The EpicentRx Team
Recent Press
- Bizzaro Cancer World. PharmaTimes. October issue 2024.
Recent Publications
- Lost at SCLC: a review of potential platinum sensitizers. Cancer and Metastasis Review. August 2024.
Relevant Blog Posts
- A September to Remember. September 2024
- Lost at SCLC. August 2024.
- InferNO. August 2024.
- Divert Shields! July 2024.
- Enter the Epicenter. July 2024.